Cencora (COR) has
consistently beaten earnings estimates, seeing purchases from LSV Asset Management, Csenge Advisory Group, Empirical Finance LLC, and others. Despite a setback from a decision by Walgreens, the
long-term stock value has remained strong; this is bolstered by Robert W. Baird's raised price target to $285. Some investors believe shares are
undervalued by 43%. Insider sales from CEO Steven Collis and Executive VP Gina Clark have arisen, yet, the stock still hit a
52-week high. Concerns over ambiguous valuations and
data breach risks exist, as do bearish signals from insiders disposing stock. Despite this, Cencora
outperformed the healthcare sector, beat EPS, and saw further purchase by AMF Tjanstepension AB and Mirae Asset Global Investments, among others. However, earnings did
miss expectations, casting doubt on investment security. Still, it remains undervalued with significant growth potential. Q2 earnings showed an
adjusted EPS exceeding expectations and a
raised full-year guidance. In response to a bottom-line miss in Q1, the
CEO Steven Collis announced his retirement, with a successor named. Notably, the
company is buying back shares to boost shareholder value and closed a $500 million senior notes offering.
Cencora COR News Analytics from Wed, 30 Aug 2023 07:00:00 GMT to Sun, 14 Jul 2024 11:06:08 GMT -
Rating 4
- Innovation -1
- Information 6
- Rumor -3
